Scarica l'app Stockscreener
0.7238
0.39%
0.0028
Precedente Chiudi:
$0.721
Aprire:
$0.7198
Volume 24 ore:
87,289
Relative Volume:
0.22
Capitalizzazione di mercato:
$23.20M
Reddito:
-
Utile/perdita netta:
$-51.23M
Rapporto P/E:
-0.5612
EPS:
-1.2898
Flusso di cassa netto:
$-41.53M
1 W Prestazione:
-11.66%
1M Prestazione:
-26.14%
6M Prestazione:
-76.95%
1 anno Prestazione:
-76.35%
Intervallo 1D:
$0.7198
$0.7586
Intervallo di 1 settimana:
$0.6853
$0.833
Portata 52W:
$0.6844
$5.75
Skye Bioscience Inc Stock (SKYE) Company Profile
Nome
Skye Bioscience Inc
Settore
Industria
Telefono
(858) 410-0266
Indirizzo
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE vs SHMD, GOODO, PSNYW, DWLD, QQQE
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
7.55 | 483.19M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.30 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
3.00 | 268.25M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DWLD
Davis Select Worldwide ETF
|
46.10 | 0 | 0 | 0 | 0 | 0.00 |
|
QQQE
Direxion NASDAQ-100 Equal Weigh
|
102.68 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-06 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-06 | Downgrade | Craig Hallum | Buy → Hold |
| 2025-08-15 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | William Blair | Outperform |
| 2024-09-30 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-09 | Iniziato | Craig Hallum | Buy |
| 2024-05-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-04-12 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Skye Bioscience Inc Borsa (SKYE) Ultime notizie
How do insiders feel about Skye Bioscience Inc.Dividend Hike & Weekly Breakout Opportunity Watchlist - mfd.ru
What’s the outlook for Skye Bioscience Inc.’s sector2025 Trade Ideas & AI Forecasted Entry and Exit Points - mfd.ru
Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
Geopolitics Watch: Does Skye Bioscience Inc meet Warren Buffetts criteriaQuarterly Trade Review & Reliable Price Breakout Alerts - baoquankhu1.vn
2026-02-12 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Skye Bioscience, Inc. (SKYE) And Encourages Shareholders to Connect | NDAQ:SKYE | Press Release - Stockhouse
Aug EndMonth: How does IHS Holding Limited compare to its peersJuly 2025 Institutional & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Can Skye Bioscience Inc. stock reach $100 price targetWeekly Trade Analysis & Technical Confirmation Trade Alerts - mfd.ru
Whats the outlook for Skye Bioscience Incs sectorTrade Analysis Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Retail Trends: Does Skye Bioscience Inc have a competitive edgeJuly 2025 PreEarnings & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire
Aug Analyst Calls: Will Skye Bioscience Inc benefit from government policy2025 Valuation Update & Precise Trade Entry Recommendations - baoquankhu1.vn
Movement Recap: Can Skye Bioscience Inc weather a recessionMarket Rally & Long-Term Capital Growth Strategies - baoquankhu1.vn
Here's Why Skye Bioscience (NASDAQ:SKYE) Must Use Its Cash Wisely - Sahm
H.C. Wainwright reiterates Buy rating on Skye Bioscience stock at $20 By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Skye Bioscience stock at $20 - Investing.com Australia
William Blair Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating - 富途牛牛
Skye Bioscience: Nimacimab’s Emerging Clinical Profile and Undervalued Asymmetric Risk/Reward Support Buy Rating - TipRanks
Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year - Benzinga
Skye Bioscience (SKYE) Reports Promising Results from CBeyond Ex - GuruFocus
Skye Bioscience announces 52-week data from Phase 2a CBeyond study of nimacimab - TipRanks
Skye reports positive Cbeyond phase 2a extension interim study results for nimacimab - marketscreener.com
Skye Bioscience Reports Interim Results from Phase 2a Study of Nimacimab - TradingView
Skye, Inc. Announces Interim Results from the Combination Cohort of the Company's Phase 2A Extension Study of Nimacimab - marketscreener.com
Obesity drug combo keeps weight off: Skye study shows 22.3% loss - Stock Titan
Chart Watch: Can Skye Bioscience Inc weather a recessionWeekly Trend Summary & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Skye Bioscience accelerates nimacimab clinical trial timeline with early enrollment and extended treatment period - MSN
2026-02-01 | Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Stockholders to Inquire about Securities Investigation | NDAQ:SKYE | Press Release - Stockhouse
Skye Bioscience reports positive results for obesity drug nimacimab By Investing.com - Investing.com South Africa
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Skye Bioscience reports positive results for obesity drug nimacimab - Investing.com
Skye Bioscience (SKYE) Highlights Promising Obesity Treatment Re - GuruFocus
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference - The Manila Times
Skye Bioscience Highlights Attributes of its - GlobeNewswire
Investment Report: Can Skye Bioscience Inc beat the S P 500Earnings Miss & Safe Capital Growth Stock Tips - baoquankhu1.vn
Portfolio Shifts: Will CREG stock hit new highs in YEARJuly 2025 WrapUp & Smart Money Movement Tracker - baoquankhu1.vn
2026-01-27 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Skye Bioscience, Inc. (SKYE) and Encourages Stockholders to Learn More About the Investigation | NDAQ:SKYE | Press Release - Stockhouse
Revenue Check: Can Skye Bioscience Inc beat the S P 5002025 Volume Leaders & Weekly Top Stock Performers List - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Investors to Inquire about Securities Investigation - accessnewswire.com
2026-01-25 | Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Investors to Inquire about Securities Investigation | NDAQ:SKYE | Press Release - Stockhouse
Aug Retail: Can Skye Bioscience Inc weather a recessionEarnings Recap Summary & Detailed Earnings Play Strategies - baoquankhu1.vn
Skye Bioscience to Present Research on Nimacimab at Keystone Conference on Obesity Therapeutics - Quiver Quantitative
Skye Bioscience to Present Poster at Keystone Obesity Conference - The Manila Times
Resistance Check: Will Skye Bioscience Inc outperform the market in YEAR2025 Investor Takeaways & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Skye Bioscience, Inc. (SKYE) And Encourages Stockholders to Reach Out - ACCESS Newswire
Skye Bioscience shares rise on Halozyme partnership to advance obesity treatment - MSN
Skye Bioscience Faces Class Action for Securities Fraud, Investors Encouraged to Join - Intellectia AI
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Se - GuruFocus
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
SKYE DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Skye Bioscience, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bios - GuruFocus
Skye Bioscience, Inc. Class Action Reminder: Lead Plaintiff Deadline January 16, 2026 - Intellectia AI
Skye Bioscience Inc Azioni (SKYE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Skye Bioscience Inc Azioni (SKYE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schwab Andrew J. | Director |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 22 '25 |
Sale |
3.42 |
170,449 |
582,936 |
57,493 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):